삼성바이오에피스 임상시험

삼성바이오에피스이(가) 진행한 임상시험의 단계, 대상 질환, 공개된 결과를 정리했습니다.

• A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaqu
  3상 · Psoriasis · 완료 · 2025년 5월 25일
• A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
  3상 · Postmenopausal Osteoporosis · 완료 · 2025년 1월 9일
• A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
  2상 · Neovascular Age-related Macular Degeneration · 완료 · 2024년 12월 30일
• A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
  3상 · Lung Cancer · 완료 · 2024년 12월 16일
• A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haem
  3상 · Paroxysmal Nocturnal Hemoglobinuria · 완료 · 2024년 3월 26일
• A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Ma
  3상 · Neovascular Age-related Macular Degeneration · 완료 · 2024년 2월 5일
• A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed
  단계 해당 없음 · Breast Neoplasms · 조기 종료 · 2024년 2월 2일
• A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related
  3상 · Age-Related Macular Degeneration · 완료 · 2021년 5월 21일
• Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects
  1상 · Healthy · 완료 · 2019년 6월 4일
• Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects
  1상 · Healthy · 완료 · 2019년 6월 3일
• An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syring
  2상 · Rheumatoid Arthritis · 완료 · 2019년 4월 1일
• Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects
  1상 · Healthy · 완료 · 2019년 3월 18일
• Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects
  1상 · Healthy · 완료 · 2019년 2월 21일
• Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects
  1상 · Healthy · 완료 · 2018년 9월 21일
• A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer
  3상 · HER2 Positive Early or Locally Advanced Breast Cancer · 완료 · 2018년 10월 24일

기업별 임상

화이자머크(MSD)로슈노바티스아스트라제네카존슨앤드존슨(얀센)BMS사노피GSK일라이 릴리애브비암젠바이엘베링거인겔하임노보 노디스크다케다길리어드모더나바이오엔테크리제네론버텍스바이오젠다이이찌산쿄아스텔라스에자이오츠카세르비에인사이트셀트리온삼성바이오에피스한미약품유한양행

전체 임상